cost-effectiveness Archives -

After two decades taking on pharma over price, Sir Andrew Dillon steps down from NICE

https://pharmaphorum.com/news/after-two-decades-taking-on-pharma-over-price-sir-andrew-dillon-steps-down-from-nice/

Scotland’s cost regulator rejects Vertex cystic fibrosis drugs

https://pharmaphorum.com/news/scotlands-cost-regulator-rejects-vertex-cystic-fibrosis-drugs/

NICE recommends funding for psoriasis and type 1 diabetes drugs

https://pharmaphorum.com/news/nice-recommends-funding-for-psoriasis-and-type-1-diabetes-drugs/

J&J’s Spravato for depression ‘should be much cheaper’

https://pharmaphorum.com/news/jjs-spravato-for-depression-should-be-much-cheaper/

NICE rejects Alnylam and Akcea’s amyloidosis drugs

https://pharmaphorum.com/news/nice-rejects-alnylam-and-akceas-amyloidosis-drugs/

AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE

https://pharmaphorum.com/news/abbvies-cll-drug-venclyxto-too-expensive-for-nhs-says-nice/

Novartis challenges court ruling allowing use of Avastin in wet AMD

https://pharmaphorum.com/news/novartis-challenges-court-ruling-allowing-use-of-avastin-in-wet-amd/

Value-based healthcare: What’s it worth to you?

https://pharmaphorum.com/views-and-analysis/value-based-healthcare-whats-worth/

Call for new restrictions on UK vaccine prices

https://pharmaphorum.com/news/uk-report-calls-new-restrictions-vaccine-prices/

Search